The life sciences sector is at a crossroads as the FDA updates quality management standards. AI is now expected, and the FDA’s January 2025 draft guidance outlines its evaluation and implementation. Successful adoption depends on three key questions.
Safe and Sane: Understanding the FDA’s Risk-Based Approach to AI
Related Posts
ARCH Motorcycle partners with Hexagon
Hexagon’s Manufacturing Intelligence division and ARCH Motorcycle, a manufacturer of high-performance bespoke motorcycles, have partnered to support the…
ZOLLER Celebrates 80 Years at Ann Arbor Open House & Technology Days
ZOLLER celebrated its 80th anniversary at its North American headquarters located in Ann Arbor, MI, with a three-day Open…
Pleora RapidPIX Compression
Patented RapidPIX™ lossless compression helps designers boost performance without adding costs by increasing data throughput over installed Ethernet…